Donor PD-L1 is required for organ transplant tolerance in MHC-mismatched mixed chimeras while PD-L1 and MHCII are not required for inducing chimerism.

[1]  S. Strober,et al.  Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans , 2022, Frontiers in Immunology.

[2]  M. Sykes,et al.  Chimerism-Based Tolerance to Kidney Allografts in Humans: Novel Insights and Future Perspectives , 2022, Frontiers in Immunology.

[3]  A. Sharpe,et al.  Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms , 2021, JCI insight.

[4]  Xiaofeng Zhu,et al.  Engineered Small Extracellular Vesicles as a FGL1/PD‐L1 Dual‐Targeting Delivery System for Alleviating Immune Rejection , 2021, bioRxiv.

[5]  A. Riggs,et al.  Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. , 2021, Blood.

[6]  A. Riggs,et al.  Reversal of autoimmunity by mixed chimerism enables reactivation of β cells and transdifferentiation of α cells in diabetic NOD mice , 2020, Proceedings of the National Academy of Sciences.

[7]  Loise M. Francisco,et al.  PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance , 2020, The Journal of experimental medicine.

[8]  L. Boon,et al.  The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. , 2020, Cancer cell.

[9]  A. Riggs,et al.  Haploidentical mixed chimerism cures autoimmunity in established type 1 diabetic mice. , 2020, The Journal of clinical investigation.

[10]  T. Wekerle,et al.  Distinct roles for major and minor antigen barriers in chimerism‐based tolerance under irradiation‐free conditions , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  W. Baldwin,et al.  Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1/PD-L1) interactions in murine kidney transplants. , 2020, Kidney international.

[12]  P. Lavori,et al.  Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal , 2020, Science Translational Medicine.

[13]  S. Berger,et al.  TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. , 2019, Immunity.

[14]  D. Cooney,et al.  A Skin Rejection Grading System for Vascularized Composite Allotransplantation in a Preclinical Large Animal Model , 2019, Transplantation.

[15]  Hiromasa Morikawa,et al.  PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer , 2019, Proceedings of the National Academy of Sciences.

[16]  Paul J. Martin,et al.  Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80 , 2018, Front. Immunol..

[17]  L. Zon,et al.  PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes , 2017, Science Translational Medicine.

[18]  M. Sykes,et al.  Mechanisms of Mixed Chimerism-Based Transplant Tolerance. , 2017, Trends in immunology.

[19]  Mingfeng Zhang,et al.  PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells , 2017, The Journal of clinical investigation.

[20]  A. Rudensky,et al.  Stability and function of regulatory T cells expressing the transcription factor T-bet , 2017, Nature.

[21]  Freeman,et al.  PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity , 2017, The Journal of experimental medicine.

[22]  F. Rivadeneira,et al.  Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. , 2016, Journal of hepatology.

[23]  S. Strober.  Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants. , 2016, Blood.

[24]  A. Riggs,et al.  MHC-mismatched mixed chimerism augments thymic regulatory T-cell production and prevents relapse of EAE in mice , 2015, Proceedings of the National Academy of Sciences.

[25]  Jonathan L. Linehan,et al.  CD4+ T cell anergy prevents autoimmunity and generates regulatory T cell precursors , 2015, Nature Immunology.

[26]  L. Boon,et al.  PD‐1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells , 2014, European journal of immunology.

[27]  J. Gordon,et al.  Distinct contributions of Aire and antigen-presenting-cell subsets to the generation of self-tolerance in the thymus. , 2014, Immunity.

[28]  M. Abecassis,et al.  Evolving Approaches of Hematopoietic Stem Cell–Based Therapies to Induce Tolerance to Organ Transplants: The Long Road to Tolerance , 2013, Clinical pharmacology and therapeutics.

[29]  A. Sharpe,et al.  Role of the PD‐1 Pathway in the Immune Response , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  Lieping Chen,et al.  Loss of B7-H1 Expression by Recipient Parenchymal Cells Leads to Expansion of Infiltrating Donor CD8+ T Cells and Persistence of Graft-Versus-Host Disease , 2012, The Journal of Immunology.

[31]  B. Levine,et al.  The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells , 2011, Science Translational Medicine.

[32]  S. Beyaz,et al.  LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. , 2011, Blood.

[33]  B. Solomon,et al.  Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis , 2011, Proceedings of the National Academy of Sciences.

[34]  Clare L. Bennett,et al.  Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. , 2010, The Journal of clinical investigation.

[35]  B. Hall,et al.  CD4+CD25+ T cells alloactivated ex vivo by IL-2 or IL-4 become potent alloantigen-specific inhibitors of rejection with different phenotypes, suggesting separate pathways of activation by Th1 and Th2 responses. , 2009, Blood.

[36]  R. Steinman,et al.  CD8+CD205+ Splenic Dendritic Cells Are Specialized to Induce Foxp3+ Regulatory T Cells1 , 2008, The Journal of Immunology.

[37]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[38]  T. Fehr,et al.  Rapid Deletional Peripheral CD8 T Cell Tolerance Induced by Allogeneic Bone Marrow: Role of Donor Class II MHC and B Cells1 , 2008, The Journal of Immunology.

[39]  M. Sayegh,et al.  Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells , 2008, Proceedings of the National Academy of Sciences.

[40]  V. Sharma,et al.  HLA-mismatched renal transplantation without maintenance immunosuppression. , 2008, The New England journal of medicine.

[41]  A. Sharpe,et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance , 2006, The Journal of experimental medicine.

[42]  Xinchun Chen,et al.  Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10 , 2006, Cancer Immunology, Immunotherapy.

[43]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[44]  M. Sykes,et al.  Mixed chimerism and transplant tolerance. , 2001, Immunity.

[45]  M. Jenkins,et al.  Regulatory T Cells + the Presence of Foxp3 Anergic State in hi CD73 hi Acquire an FR4 T Cells + Arthritogenic Self-Reactive CD4 , 2011 .

[46]  Silviu Itescu,et al.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.